Navigation Links
Bretylol, Urine

ProductsBretylol, Urine
Company ARUP Laboratories
Item Bretylol, Urine
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Clinitek 500 Urine Chemistry Analyzer
2. Clinitek Atlas Automated Urine Chemistry Analyzer (Rack)
3. Chemstrip 101 Urine Analyzer
4. Clinitek Atlas Automated Urine Chemistry Analyzer (Carousel)
5. Urisys 1100 Urine Analyzer
6. Criterion™ II Urine Analyzer
7. DiaScreen 50 Urine Chemistry Analyzer
8. FSH Home Menopause Test Midstream (Urine)
9. FSH Home Menopause Test Device (Urine)
10. Acon One Step Ovulation Test Device (Urine)
11. One Step LH Urine Ovulation Test
Precision near-field imaging combined with the best handling IVUS catheter.
Full Digital Ultrasound System
...cho technology constructs images using second harm...and noise than fundamental-frequency components.,...ansmit distortion-free, fundamental-frequency ultr...ltrasound beam is a pure sinusoidal wave, both the...
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...has not yet prepared dinner for husband Akito, as ...arm laborer, but gambles away whatever he earns. /... often ill, and fearful. Today all three are huddl...s fury. Scenario 2: Madhya Pradesh, India: Rani, ...
...on (CBI) of India on Monday conducted raids in var... the four Indian cities Delhi, Bangalore, Trivandr...e collected important information in connection wi...pments from Pharmaceutical companies. The CBI off...
...taking its toll on Hong Kong teachers, with one in..., a survey has said.// Shouting at students in the... Kong. A survey said dry throats and husky and ha...ymptoms reported by teachers, with female sufferer...
...w study demonstrates that relatives of people with... behaviours linked to the condition, even though t.../ The work, reported in the New Scientist , was ... Society of Neuroscience, in Washington DC by Dr E...
Other Medicine News:Health News:Domestic Violence: The Silent Killer of Women Worldwide 2Health News:Domestic Violence: The Silent Killer of Women Worldwide 3
(Date:9/4/2008)...trates potent antiviral activity and favorable saf...RIDGE, Mass., Sept. 4 /- Id...pharmaceutical company engaged,in the discovery an...viral,and other infectious diseases, today announc...y evaluating IDX899, a non-nucleoside reverse,tran...
(Date:9/3/2008)...stion Asked. Wrong Children Studied. Wrong,Conclus...ewswire/ -- A Centers for Disease,Control and Prev...no link,between the MMR vaccine and autism. The Na...es nothing to dispel the growing public concern ov...questions concerning design,and methodology., For...
(Date:9/3/2008)...s National Vascular Disease Awareness Month, CHAR...n Pharmaceuticals,LLC, a clinical-stage drug-devel...reatment of unmet medical needs, announced today t...I clinical trial of its lead drug,candidate trans ...T00725881,on the clinicaltrials.gov Website, is in...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Patients over age 60 do well after liver transplantation 2645 1Patients over age 60 do well after liver transplantation 2645 2Toy Blocks Might Boost Toddlers Language Skills 2644 1Toy Blocks Might Boost Toddlers Language Skills 2644 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 1HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 3Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 1Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 2
...4, 2007 /PRNewswire-FirstCall/ Haemacure,Corporati...mpany,today announced the preliminary findings of...s. , Preliminary findings confirm the presence of ... in significant worldwide,markets, including album...findings take on a strategic significance for Haem...
... 2007 /PRNewswire-FirstCall/ --,Bristol-Myers Squi...fficacy and safety of ORENCIA(R) (abatacept) from ... study in children with juvenile,idiopathic arthri...ne or more disease-modifying anti- rheumatic drugs...rosis factor (TNF) antagonists.,The results demons...
Other Medicine Technology:Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 2Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 3Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6